CytoMed Therapeutics Limited share price logo

CytoMed Therapeutics Limited

NASDAQ: GDTC

$0.90

-0.09

(-9.11%)

as on

CytoMed Therapeutics Limited Stock Performance

as on July 28, 2026 at 6:59 am IST

  • Day's Low

    Day's High

    $0.83
    $0.95
    downward going graph

    7.76%

    Downside

    5.58%

    Upside

    downward going graph

  • 52 Week's Low

    52 Week's High

    $0.68
    $3.68
    downward going graph

    24.42%

    Downside

    308.98%

    Upside

    downward going graph

CytoMed Therapeutics Limited share price movements today

Previous Close
$0.99
Open
$0.95
Volume
426.2K
Day's Low - High
$0.83 - $0.95
52 Week Low - High
$0.68 - $3.68

CytoMed Therapeutics Limited Historical Returns

1 Month Return
-2.94 %
3 Month Return
+ 10 %
1 Year Return
-47.89 %
3 Year Return
-76.71 %
5 Year Return
0 %

CytoMed Therapeutics Limited Stock Fundamentals & Key Indicators

Check CytoMed Therapeutics Limited market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.

Market Cap

$11.7M

EPS (TTM)

0

Dividend Yield

0.00%

Quarterly Earnings Growth YOY

0.00%

PE Ratio (TTM)

0

PEG Ratio

0

EBITDA

-3.8M

Revenue (TTM)

860.8K

Profit Margin

0.00%

Return On Equity TTM

-50.28%

CytoMed Therapeutics Limited vs Peer Comparison

Compare market cap, revenue, PE, and other key metrics of CytoMed Therapeutics Limited with its industry peers.

Company
Analyst View
Market Cap
5 Years Return %PE RatioProfit Margin %Dividend Yield %
CytoMed Therapeutics Limited image
CytoMed Therapeutics Limited
BUY$11.7MNANA0.00%NA
Revolution Medicines Inc. image
Revolution Medicines Inc.
BUY$40.2B539.29%NA0.00%NA
Vertex Pharmaceuticals Inc. image
Vertex Pharmaceuticals Inc.
BUY$121.2B136.04%28.3335.51%NA
Regeneron Pharmaceuticals Inc. image
Regeneron Pharmaceuticals Inc.
BUY$68.8B11.87%16.0229.65%0.5499999999999999%

Stock Returns calculator for CytoMed Therapeutics Limited Stock including INR - Dollar returns

The CytoMed Therapeutics Limited stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Impact: The bonus return you make when the US Dollar rises against the Rupee; calculated on the full amount you walk away with, not just what you invested in.

Investment Value

₹1,00,000

  • 1Y

  • 3Y

CytoMed Therapeutics Limited investment value today

Current value as on today

₹52,385

Returns

-₹47,615

(-47.61%)

Returns from CytoMed Therapeutics Limited Stock

-₹52,642 (-52.64%)

Dollar Impact

₹5,027 (+5.03%)

Analyst Recommendation on CytoMed Therapeutics Limited Stock

Based on 7 analysts

BUY

85.71%

Buy

14.29%

Hold

0.00%

Sell

Based on 7 analysts, 85.71% of analysts recommend a 'BUY' rating for CytoMed Therapeutics Limited. Average target price of $5

CytoMed Therapeutics Limited Share Price Target

Get share price movements and forecasts by analysts on CytoMed Therapeutics Limited.

What analysts predicted

82%UPSIDE

Target Price

$5

Current Price

$0.8998

Analyzed by

7 Analysts

Target

$5.00

CytoMed Therapeutics Limited target price $5, a slight upside of 82% compared to current price of $0.8998. According to 7 analysts rating.

Indian Investors' Interest in CytoMed Therapeutics Limited Stock

Search interest for CytoMed Therapeutics Limited Stock has decreased by -4% in the last 30 days, reflecting a downward trend in search activity.

Time period: to

Change:-4% versus previous 30 day period

CytoMed Therapeutics Limited Quarterly Profit & Loss

All numbers in Millions USD

Jun 2023
Sep 2023
Mar 2024
Jun 2024
Sep 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Total Revenue
0
0
0
0
0
0
0
0
0
Gross Profit
0
0
0
0
0
0
0
0
0
Operating Income
-1
0
0
0
0
0
0
0
-2
EBITDA
-1
0
0
0
0
-1
-1
0
-2
Interest Expense
0
-
0
0
-
0
0
0
0
Depreciation
-
-
-
-
-
-
-
-
-
Income Before Tax
-2
0
0
0
0
-1
-1
0
-1
Income Tax Expense
0
0
0
0
-
-
-
-
-
Net Income
-1
0
0
-1
0
-1
-1
0
-1
Net Profit Margin
-759.31%
-883.54%
-485.50%
-977.37%
-511.59%
-834.69%
-834.68%
-423.42%
-1030.69%

CytoMed Therapeutics Limited Annual Profit & Loss

All numbers in Millions USD

Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Dec 2025
Total Revenue
0
0
0
0
0
0
Gross Profit
0
0
0
0
0
0
Operating Income
-1
-1
-2
-1
-3
-4
EBITDA
-1
-1
-1
-3
-1
-4
Interest Expense
0
0
0
0
0
0
Depreciation
0
0
0
0
0
0
Income Before Tax
-1
-2
-3
-4
-2
-3
Income Tax Expense
0
0
0
0
0
-
Net Income
-1
-1
-2
-3
-1
-3
Net Profit Margin
-4323.24%
-2463.45%
-835.73%
-813.99%
-3621.10%
-1227.07%

CytoMed Therapeutics Limited Quarterly Cash Flow

All numbers in Millions USD

Sep 2023
Dec 2023
Mar 2024
Jun 2024
Sep 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Net Income
0
-1
0
0
0
-1
-2
0
-1
Operating Cash Flow
0
-1
0
-1
0
0
-1
-1
-2
Investing Cash Flow
1
-
0
-1
1
0
0
0
0
Financing Cash Flow
0
0
0
0
0
0
0
0
0
Change in Cash
-5
0
-1
-3
-
0
-1
-
0

CytoMed Therapeutics Limited Annual Cash Flow

All numbers in Millions USD

Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Dec 2025
Net Income
-1
-2
-3
-4
-2
-3
Operating Cash Flow
0
-1
-1
-3
-2
-3
Investing Cash Flow
0
0
0
-2
1
0
Financing Cash Flow
1
4
0
10
0
0
Change in Cash
0
1
0
4
-1
-2

Global Institutional Holdings in CytoMed Therapeutics Limited

Funds
Holdings
Advisor Group Holdings, Inc.
0%
StoneX Group Inc
0%
XTX Topco Ltd
0.09%
UBS Group AG
0.05%

Insights on CytoMed Therapeutics Limited

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

  • imgNO EFFECT

    Against Peers

    img

    In the last 1 year, Revolution Medicines, Inc. Common Stock has given 399.2% return, outperforming this stock by 446.1%

  • imgNO EFFECT

    Against Peers

    img

    In the last 3 years, Revolution Medicines, Inc. Common Stock has given 651.8% return, outperforming this stock by 727.5%

  • imgNEGATIVE IMPACT

    Price Dip

    img

    In the last 1 year, GDTC stock has moved down by -46.9%

  • imgNEGATIVE IMPACT

    Revenue Fall

    img

    Revenue is down for the last 2 quarters, 205.08K → 167.94K (in $), with an average decrease of 18.1% per quarter

  • imgNEGATIVE IMPACT

    Profit Down

    img

    Netprofit is down for the last 2 quarters, -868.34K → -1.73M (in $), with an average decrease of 99.3% per quarter

About CytoMed Therapeutics Limited

CytoMed Therapeutics Limited, a clinical stage biopharmaceutical company, focuses on developing novel cell-based immunotherapies for the treatment of human cancers and degenerative diseases in Malaysia and Singapore. The company's lead product candidate is CTM-N2D, an expanded gamma delta T cells grafted with natural killer group 2D ligands-targeting chimeric antigen receptor, which is in Phase I clinical trials comprising to improve anti-cancer cytotoxicity. It is also developing iPSC-gdNKT, a pluripotent stem cell-derived gamma delta natural killer T cells platform for cancer treatment; CTM-GDT, a product candidate that consists of expanded allogeneic gamma delta T cells and exploits the potential of the cells to recognize and treat a broad range of cancers; and CTM-MSC, an injectable allogeneic umbilical cord-derived mesenchymal stem cells for cartilage injury. It has research collaboration agreement with Sengkang General Hospital to provide CTM-MSC and its conditioned media for in vivo studies and Phase I clinical trial in Singapore; and Business and Research Collaboration Agreement with SunAct Cancer Institute Private Limited to conduct clinical trials for the GMP grade CTM-GDT. CytoMed Therapeutics Limited was incorporated in 2018 and is headquartered in Singapore.
OrganisationCytoMed Therapeutics Limited
Headquarters1 Commonwealth Lane, Singapore, Singapore, 149544
IndustryBiotechnology
CEOMr. Chee Kong Choo
E-voting on sharesClick here to vote

Key Management of CytoMed Therapeutics Limited

Name

Title

Dr. Jieming Zeng M.D., Ph.D.

Chief Scientific & Medical Officer and Director

Ms. Yvonne Goh

Chief Financial Officer

Dr. Tien Wee Luk M.D.

Chief Clinical Officer

Ms. Yoong Ying Tan

Chief Corporate Officer

Mr. Chee Kong Choo

Executive Chairman

FAQs

What is CytoMed Therapeutics Limited share price today?

CytoMed Therapeutics Limited share price today is $0.90 as on at the close of the market. CytoMed Therapeutics Limited share today touched a day high of $0.95 and a low of $0.83.

What is the 52 week high and 52 week low for CytoMed Therapeutics Limited share?

CytoMed Therapeutics Limited share touched a 52 week high of $3.68 on and a 52 week low of $0.68 on . CytoMed Therapeutics Limited stock price today i.e. is closed at $0.90,which is 75.55% down from its 52 week high and 32.30% up from its 52 week low.

What is CytoMed Therapeutics Limited's market capitalisation today?

CytoMed Therapeutics Limited market capitalisation is $0.00T as on .

How to invest in CytoMed Therapeutics Limited Stock (GDTC) from India?

  1. Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
  2. Step 2: Search for CytoMed Therapeutics Limited on INDmoney app. Click on Buy button. You can invest as low as $1.5 in CytoMed Therapeutics Limited Shares that will get you 1.6670 shares as per CytoMed Therapeutics Limited share price of $0.90 per share as on July 28, 2026 at 1:29 am IST.

What is the minimum amount required to buy CytoMed Therapeutics Limited Stock (GDTC) from India?

Indian investors can start investing in CytoMed Therapeutics Limited (GDTC) shares with as little as ₹95.9 or $1 (as of ) using the INDmoney app.
For example: If you want to invest $10 or ₹959.00 in CytoMed Therapeutics Limited stock (as per the Rupee-Dollar exchange rate as on ). Based on CytoMed Therapeutics Limited share’s latest price of $0.90 as on July 28, 2026 at 1:29 am IST, you will get 11.1136 shares of CytoMed Therapeutics Limited. Learn more about fractional shares .